Surmodics to Present at Oppenheimer Healthcare Conference

March 14, 2017 at 9:39 AM EDT

Webcast is Live on Tuesday, March 21, at 10:55 a.m. (ET)

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Mar. 14, 2017-- Surmodics, Inc. (Nasdaq:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and information systems and chief financial officer, will make a presentation to the investment community at the Oppenheimer Healthcare Conference in New York City on Tuesday, March 21, 2017, at 10:55 a.m. ET (9:55 a.m. CT).

A live audio webcast of the presentation, with accompanying slides, can be accessed by going to the investor relations portion of the Company’s website at and clicking on the webcast icon. The webcast will be archived on the Company’s website approximately three hours after the live event and will be available for 90 days, through June 19, 2017.

About Surmodics, Inc.

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) tests and microarrays. Following two recent acquisitions of Creagh Medical and NorMedix, the Company is executing a key growth strategy for its medical device business by expanding to offer total intravascular product solutions to its medical device customers. The combination of proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities, enables Surmodics to significantly increase the value it offers with highly differentiated intravascular solutions designed and engineered to meet the most demanding requirements. With this focus on offering total solutions, Surmodics’ mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information about the company, visit The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.

Source: Surmodics, Inc.

Surmodics, Inc.
Andy LaFrence, 952-500-7000